Tevogen Inc. Interest Expense
Tevogen Inc. (TVGN) reported Interest Expense of $24.57 thousand for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-14.
Financial Statements › Expense Statement
us-gaap:InterestExpense · last filed 2025-05-14
- Tevogen Inc. interest expense for the quarter ending 2025-03-31 was $24.57K, a 84.23% decline year-over-year.
- Tevogen Inc. interest expense for the quarter ending 2024-12-31 was $15.80K, a 95.02% decline year-over-year.
- Tevogen Inc. interest expense for the quarter ending 2024-09-30 was $12.46K, a 95.85% decline year-over-year.
- Tevogen Inc. interest expense for the quarter ending 2024-03-31 was $155.79K, a 46.09% decline year-over-year.
- Tevogen Inc. interest expense for fiscal 2024 was $184.04K, a 84.74% decline from fiscal 2023.
- Tevogen Inc. interest expense for fiscal 2023 was $1.21M.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month | Interest Expense 12 month as first filed |
|---|---|---|---|---|---|
| 2025-03-31 | $24.57K 10-Q · filed 2025-05-14 | $40.37K derived: sum of 2 quarters · filed 2025-05-14 | $52.83K derived: sum of 3 quarters · filed 2025-05-14 | ||
| 2024-12-31 | $15.80K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-02 | $28.26K derived: sum of 2 quarters · filed 2025-04-02 | $184.04K 10-K · filed 2025-04-02 | ||
| 2024-09-30 | $12.46K 10-Q · filed 2024-11-19 | $168.24K 10-Q · filed 2024-11-19 | |||
| 2024-03-31 | $155.79K 10-Q · filed 2025-05-14 | $473.31K derived: sum of 2 quarters · filed 2025-05-14 | $773.25K derived: sum of 3 quarters · filed 2025-05-14 | ||
| 2023-12-31 | $317.52K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-02 | $617.47K derived: sum of 2 quarters · filed 2025-04-02 | $1.21M 10-K · filed 2025-04-02 | $256.03K 10-K · filed 2024-04-29 | |
| 2023-09-30 | $299.94K 10-Q · filed 2024-11-19 | $888.83K 10-Q · filed 2024-11-19 | |||
| 2023-03-31 | $289.00K 10-Q · filed 2024-05-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B |